Hepacivirus C

Aethlon Announces FDA Approval of IDE Supplement for COVID-19 Patients

Retrieved on: 
Thursday, June 18, 2020
Infectious diseases, Medicine, Medical specialties, Tropical diseases, RTT, Biological weapons, Zoonoses, Healthcare-associated infections, Hepacivirus C, Virus, Ebola virus disease, Hepatitis

The Hemopurifier has previously been tested in patients with hepatitis C virus (HCV) infection and in one patient with Ebola virus infection.

Key Points: 
  • The Hemopurifier has previously been tested in patients with hepatitis C virus (HCV) infection and in one patient with Ebola virus infection.
  • Timothy C. Rodell, M.D., Chief Executive Officer of Aethlon, stated, "We believe that the Hemopurifier may have the potential to help severely affected patients with COVID-19.
  • We believe that clearing circulating virus in these patients, in combination with other supportive measures, could improve outcomes in this deadly disease."
  • The Hemopurifier is an FDA designated "Breakthrough Device" for the treatment of life-threatening viruses that are not addressed with approved therapies.

Enanta Pharmaceuticals to Present at the Raymond James Human Health Innovation Conference

Retrieved on: 
Thursday, June 11, 2020
Research, Infectious diseases, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Infectious diseases, Medical specialties, Medicine, Healthcare-associated infections, RTT, Hepatitis C, Hepatitis, Liver disease, Hepacivirus C, Viral disease, Virus

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Raymond James Human Health Innovation Conference on June 18, 2020 at 10:20 a.m.
  • A live webcast will be accessible by visiting the Events and Presentations section on the Investors page of Enantas website at www.enanta.com .
  • A replay of the webcast will be available following the presentation and will be archived for approximately 30 days.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.

HealthWell Foundation Confirms Commitment to Hepatitis C Patients During Hepatitis Awareness Month

Retrieved on: 
Thursday, May 21, 2020
Medical specialties, Infectious diseases, Medicine, Infectious causes of cancer, Healthcare-associated infections, RTT, Viral diseases, Hepatitis, Hepacivirus C, Viral hepatitis, Hepacivac

GERMANTOWN, Md., May 21, 2020 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, reaffirms its commitment to supporting the Hepatitis C community during Hepatitis Awareness Month and for the long-term by offering financial assistance to eligible patients living with hepatitis C (also known as Hepatitis C Virus or HCV).

Key Points: 
  • GERMANTOWN, Md., May 21, 2020 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, reaffirms its commitment to supporting the Hepatitis C community during Hepatitis Awareness Month and for the long-term by offering financial assistance to eligible patients living with hepatitis C (also known as Hepatitis C Virus or HCV).
  • Today, most people become infected with the hepatitis C virus by sharing needles or other equipment to inject drugs.
  • According to the Centers for Disease Prevention and Control (CDC), for some people, hepatitis C is a short-term illness.
  • However, for more than 50% of people who become infected with the hepatitis C virus, it becomes a long-term, chronic infection.

Enanta Provides Update on Clinical Development Activities During COVID-19 Pandemic

Retrieved on: 
Thursday, March 26, 2020
Health, FDA, Infectious diseases, Hospitals, Clinical trials, Pharmaceutical, Biotechnology, Infectious diseases, Medical specialties, Healthcare-associated infections, Medicine, RTT, Hepatitis C, Hepatitis, Hepacivirus C, Liver disease

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported an update on its clinical trial activities in response to the COVID-19 pandemic.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported an update on its clinical trial activities in response to the COVID-19 pandemic.
  • With the safety of our clinical trial participants in mind, coupled with a desire to alleviate many of the resource constraints at clinical trial sites, Enanta has proactively decided to make adjustments to some of our clinical programs, said Jay R. Luly, President and Chief Executive Officer of Enanta.
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • This press release contains forward-looking statements, including statements with respect to the impact of COVID-19 on Enantas clinical development programs.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019

Retrieved on: 
Thursday, November 21, 2019
Biotechnology, General Health, Pharmaceutical, Health, Infectious diseases, Companies, Drugs, Infectious causes of cancer, Combination drugs, Hepatitis C, Glecaprevir/pibrentasvir, AbbVie Inc., Hepacivirus C, BlackBerry Limited

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2019.
  • Fiscal Fourth Quarter and Year Ended September 30, 2019 Financial Results
    Total revenue of $51.3 million for the three months ended September 30, 2019 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET.
  • The decrease in royalty revenue quarter over quarter was driven by lower HCV product sales as reported by AbbVie.
  • Enanta plans to issue its fiscal first quarter 2020 financial results press release, and hold a conference call regarding those results, on February 6, 2020.

Cocrystal Pharma Presents Data at the 26th International Symposium on Hepatitis C Virus and Related Viruses

Retrieved on: 
Tuesday, October 8, 2019
Medical specialties, Branches of biology, Medicine, Infectious causes of cancer, Hepatitis C virus, Viral hepatitis, Antiviral drug, Virus, Hepacivirus C, Hepatitis, HSV epigenetics, Viral evolution

Our unique structure-based platform technology has continued to bolster our confidence in its potential in the development of any antiviral drug.

Key Points: 
  • Our unique structure-based platform technology has continued to bolster our confidence in its potential in the development of any antiviral drug.
  • For additional information about theU.S.Phase 2a study of CC-31244 for the treatment of viral hepatitis C, please visit ClinicalTrials.gov and reference identifierNCT03501550.
  • The Annual International Symposium on Hepatitis C Virus and Related Viruses started in 1994 for advancement of HCV and related virus research.
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.

Cocrystal Pharma Announces Abstract Accepted for Poster Presentation at 26th International Symposium on Hepatitis C Virus and Related Viruses

Retrieved on: 
Tuesday, October 1, 2019
RTT, Medical specialties, Antiviral drug, Biocides, Virus, Medicine, Hepacivirus C, Hepatitis, Health, Infectious causes of cancer, Raymond F. Schinazi, Viral hepatitis

The details for the Companys poster presentation are as follows:

Key Points: 
  • The details for the Companys poster presentation are as follows:
    The Annual International Symposium on Hepatitis C Virus and Related Viruses started in 1994 for advancement of HCV and related virus research.
  • Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses.
  • Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.
  • The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

AbbVie Receives FDA Approval of MAVYRET® (glecaprevir/pibrentasvir) to Shorten Treatment Duration to Eight Weeks for Treatment-Naïve Patients with Chronic Hepatitis C and Compensated Cirrhosis Across All Genotypes

Retrieved on: 
Friday, September 27, 2019
RTT, Medical specialties, Medicine, Infectious diseases, Healthcare-associated infections, Combination drugs, Infectious causes of cancer, Glecaprevir/pibrentasvir, Hepatitis C, Hepatitis, Hepacivirus C, Cirrhosis

In August 2017, MAVYRET received regulatory approval in the U.S. as an 8-week, pan-genotypic treatment for treatment-nave HCV patients without cirrhosis.

Key Points: 
  • In August 2017, MAVYRET received regulatory approval in the U.S. as an 8-week, pan-genotypic treatment for treatment-nave HCV patients without cirrhosis.
  • EXPEDITION-8 is a single-arm, open-label, Phase 3b study in treatment-nave, GT1-6 chronic HCV patients with compensated cirrhosis (n=343) who received MAVYRET for 8 weeks.
  • MAVYRET is approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus (HCV) infection in adults across all major genotypes (GT1-6).
  • MAVYRET is an 8-week, pan-genotypic option for treatment-nave patients without cirrhosis or with compensated cirrhosis, who comprise the majority of people living with HCV.

Intent Solutions Joins University of Kentucky Program to Eliminate Hepatitis C in Appalachia

Retrieved on: 
Monday, July 8, 2019
Medical specialties, Infectious diseases, Medicine, Healthcare-associated infections, Infectious causes of cancer, Hepatitis C virus, RTT, Hepatitis C, Viral hepatitis, Hepatitis, Hepacivirus C, Hepacivac

Intent Solutions recently signed a contract with the University of Kentucky to manage the dispensation of hepatitis C medications to 900 individuals in the program and to use its tad dispensing system to track patient adherence to the prescribed drug regimen.

Key Points: 
  • Intent Solutions recently signed a contract with the University of Kentucky to manage the dispensation of hepatitis C medications to 900 individuals in the program and to use its tad dispensing system to track patient adherence to the prescribed drug regimen.
  • The goal of the Kentucky Viral Hepatitis Treatment Study (KeY Treat) is to eliminate the hepatitis C virus (HCV) from Perry County by treating all residents of the county who are chronically infected, especially those at highest risk for transmitting the virus.
  • "tad is uniquely suited to population health intervention programs like this one, and we are proud to be part of it," said Sam Zamarripa, CEO of Intent Solutions.
  • "Prescription adherence is important in any treatment program, but especially so in the 12-week regimen required to rid the body of hepatitis C virus (HCV)," Zamarripa said.

Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-514, its Lead Core Inhibitor for the Treatment of Hepatitis B Virus (HBV)

Retrieved on: 
Monday, July 8, 2019
Biotechnology, Health, Pharmaceutical, Clinical trials, Chemical compounds, Infectious diseases, Chemistry, Infectious causes of cancer, RTT, Healthcare-associated infections, Viral diseases, Cyclopropanes, Glecaprevir, Hepatitis C, Hepatitis, Hepacivirus C, EDP-514, Hepatitis B Virus, Enanta

The study plans to enroll approximately 98 subjects and to evaluate up to 6 dose cohorts, with EDP-514 administered orally, once daily.

Key Points: 
  • The study plans to enroll approximately 98 subjects and to evaluate up to 6 dose cohorts, with EDP-514 administered orally, once daily.
  • Receipt of Fast Track designation from the FDA emphasizes the large unmet need of patients with chronic HBV infection.
  • EDP-514, a novel class II hepatitis B virus (HBV) core inhibitor, is Enantas lead core inhibitor candidate.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is now sold by AbbVie in numerous countries as part of its newest treatment for chronic hepatitis C virus (HCV) infection.